Modality
Gene Editing
MOA
PD-L1i
Target
BET
Pathway
RNA Splicing
SchizophreniaET
Development Pipeline
Preclinical
~Mar 2011
→ ~Jun 2012
Phase 1
~Sep 2012
→ ~Dec 2013
Phase 2
~Mar 2014
→ ~Jun 2015
Phase 3
~Sep 2015
→ ~Dec 2016
NDA/BLA
~Mar 2017
→ ~Jun 2018
Approved
Sep 2018
→ Apr 2028
ApprovedCurrent
NCT06738697
2,703 pts·ET
2019-01→2028-04·Terminated
NCT05390743
2,021 pts·ET
2023-01→2027-09·Completed
NCT04651946
544 pts·Schizophrenia
2018-09→2027-11·Not yet recruiting
+1 more trial
8,146 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2026-04-284w awayPh3 Readout· ET
2027-09-051.4y awayPh3 Readout· ET
2027-11-011.6y awayPh3 Readout· Schizophrenia
2028-04-272.1y awayPh3 Readout· ET
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Approved
Not yet…
Approved
Termina…
Approved
Active
Approved
Complet…
Catalysts
Ph3 Readout
2026-04-28 · 4w away
ET
Ph3 Readout
2027-09-05 · 1.4y away
ET
Ph3 Readout
2027-11-01 · 1.6y away
Schizophrenia
Ph3 Readout
2028-04-27 · 2.1y away
ET
ActiveCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06738697 | Approved | ET | Terminated | 2703 | PFS |
| NCT05390743 | Approved | ET | Completed | 2021 | 6MWD |
| NCT04651946 | Approved | Schizophrenia | Not yet recr... | 544 | DAS28 |
| NCT06919316 | Approved | ET | Active | 2878 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA |